Peptides Similar to IGF-1 LR3

IGF-1 Variant Family Overview#

IGF-1 LR3 belongs to a family of insulin-like growth factor-1 analogs and related proteins that share structural homology and overlapping biological activity through the IGF-1 signaling axis. Understanding the differences between these variants is essential for selecting the appropriate reagent for specific research applications and for interpreting preclinical and clinical data. The principal variants compared here are IGF-1 DES (des(1-3)IGF-1), native IGF-1 (the basis for the approved drug mecasermin), and IGF-2.

All members of this family activate receptor tyrosine kinases in the insulin/IGF receptor superfamily, but they differ in their binding protein interactions, receptor selectivity, tissue distribution, and pharmacokinetic profiles.

IGF-1 DES (des(1-3)IGF-1)#

Structural Comparison#

IGF-1 DES is a naturally occurring truncation variant of IGF-1 in which the first three N-terminal amino acid residues (Gly-Pro-Glu) have been removed, yielding a 67-amino acid protein with a molecular weight of approximately 7365 Da. This truncation removes the Glu3 residue that is critical for IGFBP binding, thereby reducing (but not eliminating) IGFBP affinity.

In contrast, IGF-1 LR3 takes the opposite structural approach: rather than removing residues, it substitutes position 3 (Glu to Arg) and adds a 13-amino acid N-terminal extension, resulting in a larger 83-amino acid protein (approximately 9111.4 Da). Both modifications target the same functional outcome (reduced IGFBP binding) through different structural strategies.

IGFBP Binding Differences#

Both IGF-1 DES and IGF-1 LR3 exhibit substantially reduced binding to IGFBPs compared to native IGF-1, but the magnitude differs. IGF-1 DES retains residual IGFBP binding capacity, particularly for IGFBP-1 and IGFBP-3, though at greatly reduced levels compared to native IGF-1. IGF-1 LR3, with its dual modification strategy (charge reversal plus steric occlusion), achieves a more complete reduction in IGFBP binding, with affinity reduced by greater than 100-fold across the IGFBP family.

This difference has practical implications: in systems with high IGFBP concentrations, IGF-1 LR3 may maintain a higher free fraction and thus greater effective potency than IGF-1 DES.

Half-Life and Bioavailability#

IGF-1 DES has a very short half-life, estimated at approximately 20-30 minutes, reflecting its small size and rapid renal clearance. IGF-1 LR3, despite also having reduced IGFBP binding, exhibits a substantially longer estimated half-life of approximately 20-30 hours, likely attributable to its larger molecular size and different tissue distribution characteristics. This difference makes IGF-1 LR3 more practical for sustained cell culture supplementation.

Research Applications#

IGF-1 DES was first identified as an endogenous brain IGF-1 variant and has been particularly well studied in neuroscience research, including studies of neuronal survival, synaptic plasticity, and brain development. IGF-1 LR3 is more commonly used in general cell culture, bioprocessing, and muscle biology research. Both are used as research tools to distinguish IGFBP-dependent from IGFBP-independent IGF-1 signaling.

Mecasermin (Native IGF-1, Increlex)#

Clinical Status#

Native human IGF-1, marketed as mecasermin (Increlex, Ipsen), is the only IGF-1-based product approved by the FDA for clinical use. It is indicated for the treatment of severe primary IGF-1 deficiency (formerly known as Laron syndrome), a condition characterized by growth hormone receptor dysfunction leading to inadequate IGF-1 production despite normal or elevated growth hormone levels. This approval provides direct clinical validation of the IGF-1 signaling axis as a therapeutic target.

IGF-1 LR3 has no clinical approval and has not been evaluated in formal human clinical trials.

Structural and Pharmacological Differences#

Native IGF-1 is the unmodified 70-amino acid human protein that is fully subject to regulation by the IGFBP system. When administered as mecasermin, it binds to circulating IGFBPs (particularly IGFBP-3), enters the ternary complex with ALS, and has a pharmacokinetic profile partially mimicking endogenous IGF-1. This results in a clinical half-life of approximately 5.8 hours following subcutaneous injection, necessitating twice-daily administration.

IGF-1 LR3, with its dramatically reduced IGFBP binding, would have a fundamentally different pharmacokinetic profile if administered in vivo. The high free fraction would be expected to produce more immediate and intense IGF-1R activation, but with different tissue distribution patterns since IGFBP-mediated tissue targeting would be largely absent.

Safety Profile Comparison#

Mecasermin has an established adverse effect profile based on clinical trial data and post-marketing surveillance. Common adverse effects include hypoglycemia (the most clinically significant), injection site reactions, lipohypertrophy, tonsillar hypertrophy, and headache. More serious but less common effects include intracranial hypertension and potential concerns regarding long-term oncogenic risk associated with sustained IGF-1R activation.

IGF-1 LR3 has no established human safety profile. However, its enhanced potency due to IGFBP evasion raises the theoretical concern that adverse effects seen with mecasermin, particularly hypoglycemia and mitogenic stimulation, could be amplified.

Potency Comparison#

In cell culture systems containing serum (and therefore IGFBPs), IGF-1 LR3 is typically 2-3 fold more potent than native IGF-1 on a molar basis. This potency advantage reflects the higher free fraction rather than enhanced intrinsic receptor affinity. In IGFBP-free systems, the two proteins are comparably active.

IGF-2 (Insulin-like Growth Factor 2)#

Distinct Biology#

IGF-2 is a 67-amino acid protein that shares approximately 62% sequence identity with IGF-1. Despite this structural similarity, IGF-2 has a substantially different biological role. It is the principal insulin-like growth factor during fetal development, while IGF-1 predominates postnatally under growth hormone regulation.

IGF-2 binds to the IGF-1R with lower affinity than IGF-1 (approximately 2-15 fold lower depending on the assay system) but also binds to the IGF-2R (mannose-6-phosphate receptor), which acts primarily as a clearance receptor rather than a signaling receptor. IGF-2 also binds the insulin receptor, particularly the IR-A isoform, with relatively high affinity, which is relevant to its roles in fetal growth and in certain cancers where IR-A is overexpressed.

IGFBP Interactions#

IGF-2 is regulated by the same family of IGFBPs as IGF-1, though with different relative affinities for individual binding proteins. Notably, IGFBP-6 has a strong preference for IGF-2 over IGF-1. IGF-1 LR3 is not directly comparable to IGF-2 in terms of binding protein regulation because it was specifically engineered to evade the IGFBP system, while IGF-2 operates within normal binding protein regulation.

Relevance to IGF-1 LR3 Research#

In research contexts, IGF-2 is sometimes used alongside IGF-1 and its analogs to distinguish between IGF-1R-mediated and IR-A-mediated signaling. Since IGF-1 LR3 retains IGF-1R selectivity comparable to native IGF-1, comparing its effects with those of IGF-2 can help identify the contribution of different receptor pathways in a given experimental system.

Comparative Summary#

Evidence Gaps#

Direct head-to-head comparisons between IGF-1 LR3 and IGF-1 DES are limited in the published literature, particularly in intact biological systems rather than cell-free binding assays. The relative potency and selectivity of these analogs across different tissue types and IGFBP environments has not been comprehensively characterized. Furthermore, no clinical studies have compared the in vivo pharmacokinetics or pharmacodynamics of IGF-1 LR3 with those of mecasermin or IGF-1 DES, leaving the translational relevance of in vitro potency comparisons uncertain.

The cross-reactivity of each variant with insulin receptor isoforms at experimentally relevant concentrations remains incompletely defined, which is important for interpreting results in metabolic research contexts where both IGF-1R and IR pathways may contribute to observed effects.

Related Reading#

• IGF-1 LR3 overview and research guide
• IGF-1 LR3 research evidence
• IGF-1 LR3 dosing protocols